Effect of long-term interferon therapy for refractory chronic hepatitis C: Preventive effect on hepatocarcinogenesis

Yoshimasa Saito, Hidetsugu Saito, Shinichiro Tada, Nobuhiro Nakamoto, Hitomi Horikawa, Satoshi Kurita, Kumi Kitamura, Hirotoshi Ebinuma, Hiromasa Ishii, Toshifumi Hibi

研究成果: Article

14 引用 (Scopus)

抄録

Background/Aims: Effect of interferon (IFN) therapy for refractory chronic hepatitis C is not sufficient. For patients with persistent hepatitis C virus (HCV) infection, one of the clinical goals is prevention of progression to liver cirrhosis (LC) and hepatocellular carcinoma (HCC). In this study; we evaluated effect of long-term IFN administration for refractory chronic hepatitis C. Methodology: The patients who were positive for HCV of genotype Ib in high viral load and failed in HCV elimination by standard IFN therapy were retrospectively analyzed. The patients were divided into three groups according to administration duration of IFN therapy. The patients in group 1, 2 and 3 received IFN therapy for 6 months, 6-24 months and more than 24 months, respectively. Results: The normalization rate of alanine aminotransferase (ALT) levels less than twice that of the normal limit 6 months after the treatment was highest in group 3 (85%). The platelet counts in group 1 gradually decreased more than 3×104/μL from the pretreatment levels at 100 months after the start of treatment. Cumulative hepatocarcinogenesis rate in groups 1, 2 and 3 were 34.7%, 5.9% and 0%, respectively. We found distinct improvement in both ALT levels and histopathological findings in the case that received the longest term of IFN therapy (91 months). Conclusions: Long-term IFN therapy is effective in preventing hepatocarcinogenesis through reduction of chronic necroinflammation and accumulation of fibrosis in the liver and may he a good indication even for refractory chronic hepatitis C.

元の言語English
ページ(範囲)1491-1496
ページ数6
ジャーナルHepato-Gastroenterology
52
発行部数65
出版物ステータスPublished - 2005 9

Fingerprint

Chronic Hepatitis C
Interferons
Hepacivirus
Therapeutics
Alanine Transaminase
Liver Cirrhosis
Virus Diseases
Viral Load
Platelet Count
Hepatocellular Carcinoma
Genotype

ASJC Scopus subject areas

  • Gastroenterology

これを引用

Effect of long-term interferon therapy for refractory chronic hepatitis C : Preventive effect on hepatocarcinogenesis. / Saito, Yoshimasa; Saito, Hidetsugu; Tada, Shinichiro; Nakamoto, Nobuhiro; Horikawa, Hitomi; Kurita, Satoshi; Kitamura, Kumi; Ebinuma, Hirotoshi; Ishii, Hiromasa; Hibi, Toshifumi.

:: Hepato-Gastroenterology, 巻 52, 番号 65, 09.2005, p. 1491-1496.

研究成果: Article

Saito, Y, Saito, H, Tada, S, Nakamoto, N, Horikawa, H, Kurita, S, Kitamura, K, Ebinuma, H, Ishii, H & Hibi, T 2005, 'Effect of long-term interferon therapy for refractory chronic hepatitis C: Preventive effect on hepatocarcinogenesis', Hepato-Gastroenterology, 巻. 52, 番号 65, pp. 1491-1496.
Saito, Yoshimasa ; Saito, Hidetsugu ; Tada, Shinichiro ; Nakamoto, Nobuhiro ; Horikawa, Hitomi ; Kurita, Satoshi ; Kitamura, Kumi ; Ebinuma, Hirotoshi ; Ishii, Hiromasa ; Hibi, Toshifumi. / Effect of long-term interferon therapy for refractory chronic hepatitis C : Preventive effect on hepatocarcinogenesis. :: Hepato-Gastroenterology. 2005 ; 巻 52, 番号 65. pp. 1491-1496.
@article{0c5011ca6f994a95b4c96a5787856a21,
title = "Effect of long-term interferon therapy for refractory chronic hepatitis C: Preventive effect on hepatocarcinogenesis",
abstract = "Background/Aims: Effect of interferon (IFN) therapy for refractory chronic hepatitis C is not sufficient. For patients with persistent hepatitis C virus (HCV) infection, one of the clinical goals is prevention of progression to liver cirrhosis (LC) and hepatocellular carcinoma (HCC). In this study; we evaluated effect of long-term IFN administration for refractory chronic hepatitis C. Methodology: The patients who were positive for HCV of genotype Ib in high viral load and failed in HCV elimination by standard IFN therapy were retrospectively analyzed. The patients were divided into three groups according to administration duration of IFN therapy. The patients in group 1, 2 and 3 received IFN therapy for 6 months, 6-24 months and more than 24 months, respectively. Results: The normalization rate of alanine aminotransferase (ALT) levels less than twice that of the normal limit 6 months after the treatment was highest in group 3 (85{\%}). The platelet counts in group 1 gradually decreased more than 3×104/μL from the pretreatment levels at 100 months after the start of treatment. Cumulative hepatocarcinogenesis rate in groups 1, 2 and 3 were 34.7{\%}, 5.9{\%} and 0{\%}, respectively. We found distinct improvement in both ALT levels and histopathological findings in the case that received the longest term of IFN therapy (91 months). Conclusions: Long-term IFN therapy is effective in preventing hepatocarcinogenesis through reduction of chronic necroinflammation and accumulation of fibrosis in the liver and may he a good indication even for refractory chronic hepatitis C.",
keywords = "Hepatocarcinogenesis, Long-term IFN, Refractory hepatitis C",
author = "Yoshimasa Saito and Hidetsugu Saito and Shinichiro Tada and Nobuhiro Nakamoto and Hitomi Horikawa and Satoshi Kurita and Kumi Kitamura and Hirotoshi Ebinuma and Hiromasa Ishii and Toshifumi Hibi",
year = "2005",
month = "9",
language = "English",
volume = "52",
pages = "1491--1496",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "65",

}

TY - JOUR

T1 - Effect of long-term interferon therapy for refractory chronic hepatitis C

T2 - Preventive effect on hepatocarcinogenesis

AU - Saito, Yoshimasa

AU - Saito, Hidetsugu

AU - Tada, Shinichiro

AU - Nakamoto, Nobuhiro

AU - Horikawa, Hitomi

AU - Kurita, Satoshi

AU - Kitamura, Kumi

AU - Ebinuma, Hirotoshi

AU - Ishii, Hiromasa

AU - Hibi, Toshifumi

PY - 2005/9

Y1 - 2005/9

N2 - Background/Aims: Effect of interferon (IFN) therapy for refractory chronic hepatitis C is not sufficient. For patients with persistent hepatitis C virus (HCV) infection, one of the clinical goals is prevention of progression to liver cirrhosis (LC) and hepatocellular carcinoma (HCC). In this study; we evaluated effect of long-term IFN administration for refractory chronic hepatitis C. Methodology: The patients who were positive for HCV of genotype Ib in high viral load and failed in HCV elimination by standard IFN therapy were retrospectively analyzed. The patients were divided into three groups according to administration duration of IFN therapy. The patients in group 1, 2 and 3 received IFN therapy for 6 months, 6-24 months and more than 24 months, respectively. Results: The normalization rate of alanine aminotransferase (ALT) levels less than twice that of the normal limit 6 months after the treatment was highest in group 3 (85%). The platelet counts in group 1 gradually decreased more than 3×104/μL from the pretreatment levels at 100 months after the start of treatment. Cumulative hepatocarcinogenesis rate in groups 1, 2 and 3 were 34.7%, 5.9% and 0%, respectively. We found distinct improvement in both ALT levels and histopathological findings in the case that received the longest term of IFN therapy (91 months). Conclusions: Long-term IFN therapy is effective in preventing hepatocarcinogenesis through reduction of chronic necroinflammation and accumulation of fibrosis in the liver and may he a good indication even for refractory chronic hepatitis C.

AB - Background/Aims: Effect of interferon (IFN) therapy for refractory chronic hepatitis C is not sufficient. For patients with persistent hepatitis C virus (HCV) infection, one of the clinical goals is prevention of progression to liver cirrhosis (LC) and hepatocellular carcinoma (HCC). In this study; we evaluated effect of long-term IFN administration for refractory chronic hepatitis C. Methodology: The patients who were positive for HCV of genotype Ib in high viral load and failed in HCV elimination by standard IFN therapy were retrospectively analyzed. The patients were divided into three groups according to administration duration of IFN therapy. The patients in group 1, 2 and 3 received IFN therapy for 6 months, 6-24 months and more than 24 months, respectively. Results: The normalization rate of alanine aminotransferase (ALT) levels less than twice that of the normal limit 6 months after the treatment was highest in group 3 (85%). The platelet counts in group 1 gradually decreased more than 3×104/μL from the pretreatment levels at 100 months after the start of treatment. Cumulative hepatocarcinogenesis rate in groups 1, 2 and 3 were 34.7%, 5.9% and 0%, respectively. We found distinct improvement in both ALT levels and histopathological findings in the case that received the longest term of IFN therapy (91 months). Conclusions: Long-term IFN therapy is effective in preventing hepatocarcinogenesis through reduction of chronic necroinflammation and accumulation of fibrosis in the liver and may he a good indication even for refractory chronic hepatitis C.

KW - Hepatocarcinogenesis

KW - Long-term IFN

KW - Refractory hepatitis C

UR - http://www.scopus.com/inward/record.url?scp=25844454008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25844454008&partnerID=8YFLogxK

M3 - Article

C2 - 16201104

AN - SCOPUS:25844454008

VL - 52

SP - 1491

EP - 1496

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 65

ER -